Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Fundam Clin Pharmacol ; 17(2): 183-8, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12667228

ABSTRACT

The leishmaniases are protozoan diseases caused by Leishmania parasites. The first-line treatment of its visceral forms is pentavalent antimony (meglumine antimoniate or sodium stibogluconate), but toxicity is frequent with this drug. Moreover antimony unresponsiveness is increasing in Leishmania infantum and L. donovani foci, both in immunocompetent and in immunosuppressed patients. Amphotericin B is a polyene macrolide antibiotic that binds to sterols in cell membranes. It is the most active antileishmanial agent in use. Its infusion-related and renal toxicity may be reduced by lipid-based delivery. Liposomal amphotericin B (AmBisome); Gilead Science, Paris, France) seems to be less toxic than other amphotericin B lipid formulations (Amphocil); Liposome Technology Inc., Menlo Park, CA, USA, Amphotec); Ben Venue Laboratories Inc., Bedford, OH, USA). Optimal drug regimens of AmBisome) vary from one geographical area to another. In the Mediterranean Basin, a total dose of 18 mg/kg (3 mg/kg on days 1-5 and 3 mg/kg on day 10) could be used as first-line treatment of visceral leishmaniasis in immunocompetent patients. In immunocompromised patients, especially those co-infected with HIV, relapses are frequent with AmBisome), as with other drugs.


Subject(s)
Amphotericin B/therapeutic use , Antiprotozoal Agents/therapeutic use , Leishmaniasis, Visceral/drug therapy , Leishmaniasis, Visceral/immunology , Phosphatidylcholines/therapeutic use , Phosphatidylglycerols/therapeutic use , Amphotericin B/administration & dosage , Amphotericin B/adverse effects , Animals , Antimony Sodium Gluconate/adverse effects , Antimony Sodium Gluconate/therapeutic use , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/adverse effects , Clinical Trials as Topic , Drug Administration Schedule , Drug Combinations , Humans , Immunocompromised Host , Leishmania/drug effects , Leishmaniasis, Visceral/parasitology , Liposomes , Meglumine/adverse effects , Meglumine/therapeutic use , Meglumine Antimoniate , Organometallic Compounds/adverse effects , Organometallic Compounds/therapeutic use , Phosphatidylcholines/administration & dosage , Phosphatidylcholines/adverse effects , Phosphatidylglycerols/administration & dosage , Phosphatidylglycerols/adverse effects , Treatment Failure
2.
Eur J Immunol ; 32(5): 1319-27, 2002 05.
Article in English | MEDLINE | ID: mdl-11981819

ABSTRACT

In human peripheral blood the classical CD14(++)DR(+) monocytes and the pro-inflammatory CD14(+)CD16(+)DR(++) monocytes can be distinguished. In erysipelas we found strongly increased numbers of CD14(+)CD16(+) monocytes on the day of diagnosis (day 1) in 11 patients with an average of 150.5+/-76.0 cells/microl, while 1 patient had low levels (35 cells/microl, control donors 48.8+/-19.8 cells/microl). The classical monocytes were only moderately elevated in the erysipelas patients (factor 1.7 as compared to controls). Patients exhibited increased body temperature, erythrocyte sedimentation rate and increased serum levels for C-reactive protein (CRP), IL-6 and macrophage-colony-stimulating factor. Among these, body temperature and CRP showed a significant correlation to the numbers of CD14(+)CD16(+) monocytes. In 4 of 4 patients with high levels of CD14(+)CD16(+) monocytes, these levels returned to that seen in controls by day 5 of antibiotic therapy. Determination of intracellular TNF was performed by three-color immunofluorescence and flow cytometry after ex vivo stimulation with lipoteichoic acid, a typical constituent of streptococci. Here, patient CD14(+)DR(++) pro-inflammatory monocytes showed a twofold lower level of intracellular TNF. By contrast, expression of TNF was unaltered in the classical CD14(++) monocytes. These data show that in erysipelas the pro-inflammatory CD14(+)CD16(+)DR(++) monocytes are substantially expanded and selectively tolerant to stimulation by streptococcal products.


Subject(s)
Cytokines/biosynthesis , Erysipelas/immunology , Lipopolysaccharide Receptors/metabolism , Monocytes/immunology , Receptors, IgG/metabolism , Anti-Bacterial Agents/therapeutic use , Case-Control Studies , Erysipelas/blood , Erysipelas/drug therapy , HLA-DR Antigens/metabolism , Humans , Interferon-gamma/blood , Interleukin-10/blood , Interleukin-6/blood , Macrophage Colony-Stimulating Factor/blood , Time Factors
3.
J Immunol ; 168(7): 3536-42, 2002 Apr 01.
Article in English | MEDLINE | ID: mdl-11907116

ABSTRACT

In human blood two monocyte populations can be distinguished, i.e., the CD14(++)CD16(-)DR(+) classical monocytes and the CD14(+)CD16(+)DR(++) proinflammatory monocytes that account for only 10% of all monocytes. We have studied TNF production in these two types of cells using three-color immunofluorescence and flow cytometry on whole peripheral blood samples stimulated with either LPS or with the bacterial lipopeptide S-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys(4)-OH,trihydrochloride (Pam3Cys). After stimulation with LPS the median fluorescence intensity for TNF protein was 3-fold higher in the proinflammatory monocytes when compared with the classical monocytes. After stimulation with Pam3Cys they almost exclusively responded showing 10-fold-higher levels of median fluorescence intensity for TNF protein. The median fluorescence intensity for Toll-like receptor 2 cell surface protein was found 2-fold higher on CD14(+)CD16(+)DR(++) monocytes, which may explain, in part, the higher Pam3Cys-induced TNF production by these cells. When analyzing secretion of TNF protein into the supernatant in PBMCs after depletion of CD16(+) monocytes we found a reduction of LPS-induced TNF by 28% but Pam3Cys-induced TNF was reduced by 64%. This indicates that the minor population of CD14(+)CD16(+) monocytes are major producers of TNF in human blood.


Subject(s)
Cysteine/analogs & derivatives , Drosophila Proteins , HLA-DR Antigens/biosynthesis , Lipopolysaccharide Receptors/biosynthesis , Monocytes/immunology , Monocytes/metabolism , Receptors, IgG/biosynthesis , Tumor Necrosis Factor-alpha/biosynthesis , Adjuvants, Immunologic/pharmacology , Cells, Cultured , Cysteine/pharmacology , Fluorescent Antibody Technique , HLA-DR Antigens/blood , Humans , Immunomagnetic Separation , Immunophenotyping , Inflammation/immunology , Inflammation/pathology , Lipopolysaccharide Receptors/blood , Lipopolysaccharides/pharmacology , Lipoproteins/pharmacology , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/genetics , Monocytes/classification , RNA, Messenger/biosynthesis , Receptors, Cell Surface/biosynthesis , Receptors, Cell Surface/genetics , Receptors, IgG/blood , Receptors, Immunologic/metabolism , Toll-Like Receptor 2 , Toll-Like Receptors , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...